Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Health

Results: 6517-6528 of 8109

PR Newswire associated0

Affidea enters into an agreement to acquire MedEuropa Romania

PR Newswire associated0

Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting

PR Newswire associated0

Insightec's Groundbreaking Transcranial MR-Guided Focused Ultrasound (MRgFUS) Approved for Additional Reimbursement for Essential Tremor in Germany

Sectra's enterprise imaging solution now covers majority of US patients in the Midwest following new contract

PR Newswire associated0

RLDatix finalizes acquisition of Breitenbach Software

Business Wire logo

Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer

PR Newswire associated0

The 16th Zhang Zhongjing Medicine Culture Festival & Forum on High-quality Development of TCM Takes Place in Nanyang, China

Business Wire logo

MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120

PR Newswire associated0

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

Calliditas Therapeutics to Attend Investor Conferences in March

Ben Crosbie, CEO of The DRIPBaR and Sarah Lomas, Founder and CEO of REVIV Global, announce their exciting partnership. (Photo: Business Wire)

Wellness Market Leaders Join Forces: The DRIPBaR Powered by REVIV

iTeos to Participate in Upcoming Investor Conferences

  • Prev Page
  • 1
  • 2
  • …
  • 543
  • 544
  • 545
  • …
  • 675
  • 676
  • Next Page

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2026

Terms of Use

Privacy Policy

Contact Us